9804484-5 IPOS

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/00

A2

(11) International Publication Number: WO 98/29104

(43) International Publication Date: 9 July 1998 (09.07.98)

(21) International Application Number: PCT/JP97/04698

(22) International Filing Date: 19 December 1997 (19.12.97)

(30) Priority Data:
08/774,418 30 December 1996 (30.12.96) US

(71) Applicant: KISSEI PHARMACEUTICAL CO., LTD. [JP/JP]; 19–48, Yoshino, Matsumoto–shi, Nagano 399 (JP).

(72) Inventors: FUKUYAMA, Juichi; 5157–8, Hotaka, Hotaka–machi, Minamiazumi–gun, Nagano 399–83 (JP). MIYAZAWA, Keiji; 543, Oaza Minamihotaka, Toyoshina–machi, Minamiazumi–gun, Nagano 399–82 (JP). HAMANO, Shuichiro; 518–1, Murai–machi, Yoshikawa, Matsumoto–shi, Nagano 399 (JP). UJIIE, Arao; 6651–31, Oaza Takibe, Toyoshina–machi, Minamiazumi–gun, Nagano 399–82 (JP).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

Without international search report and to be republished upon receipt of that report.

IPD. IPC: A61K 31/195
1 applⁿ.
4 Invs.
16 PAs.

(54) Title: USE OF 2–(3,4–DIMETHOXYCINNAMOYL)AMINOBENZOIC ACID FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OR PREVENTION OF RESTENOSIS

(57) Abstract

This invention provides a use of 2–(3,4–dimethoxycinnamoyl) aminobenzoic acid as a therapeutic agent for treating patients to inhibit restenosis associated with coronary intervention, which comprises administering to a patient Tranilast or a pharmaceutically acceptable salt thereof in a dose which is effective for maintaining the plasma concentration of Tranilast at about 100 μ molar concentration, for a treatment period which prevents excessive proliferation of vascular smooth muscle cells after coronary intervention, such as a period of less than 3 months after coronary intervention. The dosage and a term of administration in an actual treatment depend on factors such as the weight, age and sex of the patient, the severity of the condition to be treated, the constitution of the patient as effecting the rate and speed of absorption, distribution, metabolism and excretion of drug of the patient, and the like.